Deliberate infection in research: ethical perspective of controlled human infection studies

Area of Science:

• Biomedical Ethics
• Infectious Disease Research
• Clinical Trial Design

Background:

• Controlled human infection studies (CHIS) are vital for understanding disease and developing vaccines.
• CHIS present ethical challenges, particularly regarding non-maleficence and lack of direct participant benefit.
• Existing ethical frameworks require re-evaluation in light of modern research needs.

Purpose of the Study:

• To review the ethical challenges associated with CHIS.
• To discuss the need for a robust, context-sensitive ethical framework for CHIS.
• To analyze ethical principles in relation to CHIS design and conduct, especially in low- and middle-income countries.

Main Methods:

• Narrative review of ethical guidelines, trial design debates, and evidence-based analyses.
• Analysis of ethical principles including proportionality, respect for persons, and social value.
• Examination of specific CHIS elements: challenge strain selection, participant and control group selection, and adverse event monitoring.

Main Results:

• CHIS involve deliberate exposure to pathogens, raising ethical concerns about potential harm without direct benefit.
• Ethical considerations are amplified in low- and middle-income countries due to factors like justice and capacity building.
• India's CHIS landscape is examined within its evolving ethical and regulatory context.

Conclusions:

• CHIS can be ethically acceptable if implemented with stringent, context-sensitive ethical standards.
• Transparency in reporting and equitable benefit sharing are crucial for maintaining public trust.
• A robust ethical framework is necessary to navigate the complexities of CHIS, ensuring participant safety and societal value.